MedTrace Logo

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

NCT01200394 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2019-03-12

Study results available
· View outcomes & findings →

Summary

PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.

Conditions

  • Diabetic Nephropathies

Interventions

DRUG

PF-00489791

Tablet, 20 mg once daily for 12 weeks

DRUG

Placebo

Tablet, placebo once daily for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-07-31
Completion
2013-08-31

Countries

  • United States
  • Australia
  • Canada
  • Denmark
  • Hong Kong
  • India
  • Malaysia
  • Mexico
  • Poland
  • Serbia
  • Slovakia
  • South Africa
  • South Korea
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01200394 on ClinicalTrials.gov